OMERS ADMINISTRATION Corp Sells 3,802 Shares of United Therapeutics Co. (NASDAQ:UTHR)

OMERS ADMINISTRATION Corp trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 34.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,310 shares of the biotechnology company's stock after selling 3,802 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in United Therapeutics were worth $2,579,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of UTHR. Wealth Enhancement Advisory Services LLC lifted its holdings in United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock valued at $1,761,000 after acquiring an additional 39 shares during the last quarter. Wedmont Private Capital acquired a new stake in United Therapeutics in the 4th quarter valued at about $466,000. Park Avenue Securities LLC raised its holdings in United Therapeutics by 18.4% during the 4th quarter. Park Avenue Securities LLC now owns 2,614 shares of the biotechnology company's stock worth $922,000 after buying an additional 407 shares during the period. Burney Co. raised its holdings in United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock worth $8,441,000 after buying an additional 12,705 shares during the period. Finally, USA Financial Formulas raised its holdings in United Therapeutics by 856.0% during the 4th quarter. USA Financial Formulas now owns 870 shares of the biotechnology company's stock worth $307,000 after buying an additional 779 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent analyst reports. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Morgan Stanley boosted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a report on Monday, April 21st. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Finally, HC Wainwright restated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $392.00.

United Therapeutics Price Performance

NASDAQ:UTHR traded up $1.43 during mid-day trading on Friday, reaching $305.35. The stock had a trading volume of 518,041 shares, compared to its average volume of 443,023. The business's 50 day moving average is $299.95 and its 200 day moving average is $340.44. United Therapeutics Co. has a fifty-two week low of $264.33 and a fifty-two week high of $417.82. The stock has a market cap of $13.77 billion, a P/E ratio of 13.41, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the prior year, the company posted $6.17 earnings per share. The firm's revenue was up 17.2% on a year-over-year basis. Equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $956,195.85. This represents a 79.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares in the company, valued at $11,261,606.58. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,500 shares of company stock worth $20,765,280. Insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.